| |
Where customer experience is our priority. Together with Fortrea –exceptional is possible. Experience Agility.
|
|
Today’s Big NewsDec 19, 2023 |
|
Slope's white paper reveals a breakthrough solution: software-guided sample workflows that ensure site compliance and keep your studies on track. Read more.
|
|
| By Annalee Armstrong uniQure’s Huntington’s disease data were deemed “noisy and difficult to interpret” in June. While a new slice of interim results from the phase 1/2 trial may not help cut through the noise, the principal investigators says efficacy signals are “on the favorable side.” |
|
|
|
By Annalee Armstrong Gilead Sciences is uploading $60 million to Compugen’s bank account plus hefty milestones down the road in exchange for the rights to a preclinical IL-18 binding protein program that includes a solid tumor asset. |
By Gabrielle Masson Otsuka is paying $65 million upfront for exclusive European licensing rights to Ionis' donidalorsen, a treatment under development for a rare genetic disease known as hereditary angioedema. |
By Gabrielle Masson After a mid-stage flop, Kronos Bio is discontinuing a cancer trial for lanraplenib and seeking a partner to continue development of the SYK inhibitor—the second acute myeloid leukemia (AML) candidate to disappoint the biotech. |
By Kevin Dunleavy In July, for Checkpoint Therapeutics, it was all about complete response rates adding momentum for its promising skin cancer candidate. Five months later, a complete response letter (CRL) has flipped the script on cosibelimab. On Monday, Checkpoint said that the U.S. regulator had rejected cosibelimab because of findings during an inspection of a facility of its third-party contract manufacturer. |
By Eric Sagonowsky Bluebird's FDA approval for sickle cell disease gene therapy Lyfgenia left something to be desired because the agency rejected a request for a priority review voucher. Without that voucher, bluebird is moving fast to try to fund its launches. |
By Heather Landi Among those who are holding off, doctors report lack of confidence in accuracy and a lack of integration or access through existing tools — as key obstacles to adoption. |
By Andrea Park With only a week left in President Biden’s review of a proposed import ban on Apple Watches containing a pulse oximetry feature, Apple is preemptively complying with the sales stoppage. |
Fierce podcastsDon’t miss an episode |
| | Children’s Specialized Hospital, part of RWJBarnabas, is providing recreation, sports and social programs for kids with special healthcare needs. This week on "Podnosis," Anastassia Gliadkovskaya sat down with Matthew McDonald, M.D., the hospital’s president and CEO, to discuss what it takes to offer these services in-house and the future of pediatric care. |
|
|---|
|
|
| WhitepaperDownload this whitepaper to discover the 3 pillars of successful PK testing and conquer bioanalytical challenges. Sponsored by: Sannova Analytical |
| WhitepaperThe road to digital health innovation is exciting but complex and requires thoughtful navigation; this whitepaper serves as your guide through this process. S3 Connected Health |
| WhitepaperqPCR Assay Design - Quantify microbial biomarkers with high sensitivity and dynamic range Sponsored by: Diversigen |
| WhitepaperStreamline your clinical cell therapy with our GMP-compliant ribonucleoprotein (RNP) manufacturing as you scale up without compromising on quality to tackle complex regulatory requirements. Sponsored by: Aldevron |
| Executive SummaryBy 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
| WhitepaperLearn about the untapped power of AI-driven insights — where innovation meetings precision, effortlessly unlocking benefits for your organization. Sponsored by: Planisware |
| Whitepaper Medical devices & consumer wearables are starting to overlap, creating risks & opportunities for traditional medical device companies as well as consumer wearables manufacturers. This paper explores pros and cons from both perspectives. Sponsored by: Blue Matter Consulting |
| Whitepaper Improving efficiency and productivity in biologics manufacturing is a longstanding goal within today’s industry, especially now as new and increasingly complex molecules are fundamentally changing technological and operational approaches to drug development. Process intensification can help accelerate this pace of innovation through advanced process development techniques and high productivity manufacturing platforms. Sponsored by: Lonza |
| Whitepaper As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more. Sponsored by: Lonza |
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| |
|
